People: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

182.20USD
17 Dec 2014
Price Change (% chg)

$4.47 (+2.52%)
Prev Close
$177.73
Open
$178.78
Day's High
$182.82
Day's Low
$176.01
Volume
1,940,560
Avg. Vol
1,168,258
52-wk High
$203.30
52-wk Low
$121.44

Search Stocks

Hallal, David 

Brief Biography

Mr. David L. Hallal is Chief Operating Officer, Director of Alexion Pharmaceuticals, Inc., effective September 16, 2014. He has been with Alexion since June 2006 and has served as Executive Vice President and Chief Commercial Officer since October 2012. Since joining Alexion, Mr. Hallal has served in senior commercial positions, including Senior Vice President, US Commercial Operations from June 2006 until November 2008, Senior Vice President, Commercial Operations Americas from November 2008 to May 2010, and then Senior Vice President, Global Commercial Operations from May 2010 until October 2012. Prior to joining Alexion, Mr. Hallal served as Vice President, Sales at OSI Eyetech from April 2004 until June 2006, where he led the U.S. launch of a first-in-class anti-VEGF therapy for age-related macular degeneration. Prior to OSI Eyetech, from 1992 until 2004, Mr. Hallal held various sales and marketing leadership positions at Amgen and Biogen Idec, where he was involved in multiple product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal received a B.A. in Psychology from the University of New Hampshire.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
610,000 -- 2,590,840 4,653,460

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 124,808 10,276,000.00
Name Fiscal Year Total

Vikas Sinha

4,201,460

Stephen Squinto

4,022,580

Clare Carmichael

--

Martin Mackay

6,261,860

John Moriarty

--

Saqib Islam

4,627,500
As Of 30 Dec 2013
Search Stocks